NASDAQ:CGTX Cognition Therapeutics (CGTX) Stock Price, News & Analysis $0.58 -0.02 (-3.06%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$0.57 -0.01 (-1.24%) As of 11/20/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Cognition Therapeutics Stock (NASDAQ:CGTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cognition Therapeutics alerts:Sign Up Key Stats Today's Range$0.56▼$0.6050-Day Range$0.58▼$1.0652-Week Range$0.55▼$1.81Volume665,093 shsAverage Volume384,446 shsMarket Capitalization$55.37 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingHold Company Overview Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule treatments for neurodegenerative diseases and other disorders affecting the central nervous system and retina. The company’s lead drug candidate, CT1812 (zervimesine), is an oral small molecule designed to target the sigma-2 receptor complex and disrupt the effects of toxic amyloid-beta oligomers on brain cells. Cognition has studied CT1812 in clinical programs for Alzheimer’s disease and dementia with Lewy bodies, and has also investigated its potential in retinal disease. Cognition Therapeutics’ work centers on developing treatments intended to protect or restore neuronal function, with research programs spanning multiple diseases for which treatment options remain limited.AI Generated. May Contain Errors. Read More Cognition Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreCGTX MarketRank™: 1.69376313945 of 5 starsCognition Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 687th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingCognition Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCognition Therapeutics has a consensus price target of $3.50, representing about 501.2% upside from its current price of $0.58.Amount of Analyst CoverageCognition Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Cognition Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Cognition Therapeutics are expected to remain at ($0.22) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cognition Therapeutics is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cognition Therapeutics is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCognition Therapeutics has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.18% of the float of Cognition Therapeutics has been sold short.Short Interest Ratio / Days to CoverCognition Therapeutics has a short interest ratio ("days to cover") of 15.27, which indicates bearish sentiment.Change versus previous monthShort interest in Cognition Therapeutics has recently decreased by 1.71%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCognition Therapeutics does not currently pay a dividend.Dividend GrowthCognition Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.15 News SentimentCognition Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cognition Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CGTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.11% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cognition Therapeutics' insider trading history. Receive CGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGTX Stock News HeadlinesHC Wainwright Reaffirms "Buy" Rating for Cognition Therapeutics (NASDAQ:CGTX)November 21 at 2:18 AM | americanbankingnews.comCognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START StudyNovember 17, 2026 | globenewswire.comA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.November 22 at 1:00 AM | Profits Run (Ad)HC Wainwright Has Positive Opinion of CGTX FY2026 EarningsNovember 13, 2026 | americanbankingnews.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Stock Now Rated "Moderate Buy" by Sell-Side BrokeragesNovember 12, 2026 | americanbankingnews.comCognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare ConferenceNovember 9, 2026 | globenewswire.comCognition's Q3 Loss Declines To $4 Mln As Phase 3 For Zervimesine In Dementia Set To BeginNovember 7, 2026 | rttnews.comCognition outlines mid-2027 Phase III start in DLB and cash runway into Q4 2027November 6, 2026 | seekingalpha.comSee More Headlines CGTX Stock Analysis - Frequently Asked Questions How have CGTX shares performed this year? Cognition Therapeutics' stock was trading at $1.35 at the start of the year. Since then, CGTX stock has decreased by 56.9% and is now trading at $0.5822. How were Cognition Therapeutics' earnings last quarter? Cognition Therapeutics, Inc. (NASDAQ:CGTX) announced its earnings results on Thursday, November, 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. Read the conference call transcript. When did Cognition Therapeutics IPO? Cognition Therapeutics (CGTX) raised $45 million in an IPO on Thursday, October 7th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share. Who are Cognition Therapeutics' major shareholders? Top institutional shareholders of Cognition Therapeutics include State Street Corp (0.37%), Tocqueville Asset Management L.P. (0.24%), Marshall Wace LLP (0.07%) and Lido Advisors LLC (0.05%). Insiders that own company stock include Lisa Ricciardi and John Brendan Doyle. View institutional ownership trends. How do I buy shares of Cognition Therapeutics? Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cognition Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cognition Therapeutics investors own include NVIDIA (NVDA), IonQ (IONQ), Palantir Technologies (PLTR), SoFi Technologies (SOFI), Tonix Pharmaceuticals (TNXP), D-Wave Quantum (QBTS) and BigBear.ai (BBAI). Company Calendar Last Earnings11/05/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CGTX's financial health is in the Yellow zone, according to TradeSmith. CGTX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CGTX CIK1455365 Webwww.cogrx.com Phone412-481-2210FaxN/AEmployees14Year Founded2007Price Target and Rating Average Price Target for Cognition Therapeutics$3.50 High Price Target$4.00 Low Price Target$3.00 Potential Upside/Downside+501.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.57% Return on Assets-40.42% Debt Debt-to-Equity RatioN/A Current Ratio6.68 Quick Ratio6.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book1.88Miscellaneous Outstanding Shares95,100,000Free Float84,535,000Market Cap$55.37 million OptionableNot Optionable Beta1.84 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:CGTX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredGold Miners Post Record Cash Flows as AI Stocks WobbleGold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.